StockNews.com started coverage on shares of Bellerophon Therapeutics (NASDAQ:BLPH – Get Rating) in a report published on Monday morning. The firm issued a sell rating on the biotechnology company’s stock.
Bellerophon Therapeutics Trading Down 4.7 %
Shares of BLPH opened at $1.02 on Monday. The stock has a market cap of $9.74 million, a PE ratio of -0.51 and a beta of 0.01. Bellerophon Therapeutics has a 1 year low of $0.67 and a 1 year high of $3.72. The stock has a 50 day simple moving average of $1.10 and a 200-day simple moving average of $1.17.
Institutional Investors Weigh In On Bellerophon Therapeutics
An institutional investor recently bought a new position in Bellerophon Therapeutics stock. Sepio Capital LP bought a new position in Bellerophon Therapeutics, Inc. (NASDAQ:BLPH – Get Rating) during the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund bought 23,800 shares of the biotechnology company’s stock, valued at approximately $29,000. Sepio Capital LP owned approximately 0.25% of Bellerophon Therapeutics at the end of the most recent reporting period. 11.92% of the stock is currently owned by hedge funds and other institutional investors.
Bellerophon Therapeutics Company Profile
Bellerophon Therapeutics, Inc, a clinical-stage therapeutics company, focuses on the development of products for the treatment of cardiopulmonary diseases in the United States. Its product includes INOpulse, a proprietary pulsatile nitric oxide delivery platform for the treatment of pulmonary hypertension.
- Get a free copy of the StockNews.com research report on Bellerophon Therapeutics (BLPH)
- Is the 60/40 Portfolio Mix Still in Vogue?
- Salesforce Cuts Labor, Shows Strong Earnings Despite Challenges
- Institutional Support for Analog Devices Remains High
- Microsoft Shares: Is it Time to Back Up the Truck?
- Three CBD Stocks to Dominate a Budding Industry
Receive News & Ratings for Bellerophon Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bellerophon Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.